• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.

作者信息

Farrell Michael P, Kummar Shivaani

机构信息

Department of Medicine, Yale Cancer Center, Yale University School of Medicine, West Haven, CT 06516, USA.

出版信息

Clin Colorectal Cancer. 2003 Feb;2(4):253-6. doi: 10.3816/CCC.2003.n.007.

DOI:10.3816/CCC.2003.n.007
PMID:12620148
Abstract
摘要

相似文献

1
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.一项关于新型草药制剂PHY906作为晚期结直肠癌患者化疗调节剂的I/IIA期随机研究。
Clin Colorectal Cancer. 2003 Feb;2(4):253-6. doi: 10.3816/CCC.2003.n.007.
2
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.一项中药 PHY906 作为晚期结直肠癌伊立替康为基础化疗的调节剂的 I 期研究。
Clin Colorectal Cancer. 2011 Jun;10(2):85-96. doi: 10.1016/j.clcc.2011.03.003. Epub 2011 Apr 22.
3
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.在5-氟尿嘧啶（5FU）治疗失败后接受伊立替康（CPT-11）作为二线化疗的转移性结直肠癌患者中，肿瘤反应、无进展生存期和毒性的预后因素。CPT-11 F205、F220、F221和V222研究组。
Br J Cancer. 2000 Aug;83(4):431-7. doi: 10.1054/bjoc.2000.1303.
4
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].伊立替康在晚期结直肠癌治疗中的应用及近期研究进展
Zhonghua Zhong Liu Za Zhi. 2006 Sep;28(9):718-9.
5
Irinotecan may extend survival in people with metastatic colorectal cancer.伊立替康可能会延长转移性结直肠癌患者的生存期。
Oncology (Williston Park). 1998 Oct;12(10):1512.
6
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.卡培他滨和伊立替康作为晚期结直肠癌的一线治疗方案。
J Clin Oncol. 2008 Apr 10;26(11):1907-8; author reply 1908-9. doi: 10.1200/JCO.2007.15.9640.
7
[Management of chemotherapy induced diarrhea].[化疗引起的腹泻的管理]
Z Gastroenterol. 2004 Jun;42(6):527-38. doi: 10.1055/s-2004-812982.
8
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.转移性结直肠癌的化疗：氟尿嘧啶加亚叶酸以及伊立替康或奥沙利铂。
Prescrire Int. 2005 Dec;14(80):230-3.
9
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.一项前瞻性、双盲、安慰剂对照、多中心、随机III期研究，旨在探讨口服布地奈德预防晚期结直肠癌患者伊立替康（CPT-11）所致腹泻的效果。
Oncology. 2005;68(4-6):326-32. doi: 10.1159/000086971. Epub 2005 Jul 12.
10
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.新霉素作为伊立替康所致腹泻的二级预防用药。
Ann Oncol. 2004 Aug;15(8):1296. doi: 10.1093/annonc/mdh310.

引用本文的文献

1
Effects of Natural Health Products in Combination with FP-Based Chemotherapy.
Pharmaceuticals (Basel). 2025 Nov 20;18(11):1767. doi: 10.3390/ph18111767.
2
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer.一项关于YIV-906联合新辅助同步放化疗用于局部晚期直肠癌患者的单臂2期临床试验。
J Gastrointest Oncol. 2024 Jun 30;15(3):1050-1059. doi: 10.21037/jgo-24-23. Epub 2024 Jun 25.
3
The effective combination therapies with irinotecan for colorectal cancer.伊立替康用于结直肠癌的有效联合疗法。
Front Pharmacol. 2024 Feb 5;15:1356708. doi: 10.3389/fphar.2024.1356708. eCollection 2024.
4
Recent Advances in (Licorice)-Containing Herbs Alleviating Radiotherapy- and Chemotherapy-Induced Adverse Reactions in Cancer Treatment.含甘草草药在减轻癌症治疗中放疗和化疗引起的不良反应方面的最新进展
Metabolites. 2022 Jun 9;12(6):535. doi: 10.3390/metabo12060535.
5
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.YIV-906 通过增强肿瘤微环境中的适应性和先天免疫来增强抗 PD1 作用，从而对抗肝细胞癌。
Sci Rep. 2021 Jun 29;11(1):13482. doi: 10.1038/s41598-021-91623-3.
6
A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.一项关于 PHY906 联合卡培他滨治疗肝细胞癌的 II 期临床试验。
Oncologist. 2021 Mar;26(3):e367-e373. doi: 10.1002/onco.13582. Epub 2020 Nov 25.
7
Herbal Medicines for Irinotecan-Induced Diarrhea.用于治疗伊立替康所致腹泻的草药药物。
Front Pharmacol. 2019 Mar 29;10:182. doi: 10.3389/fphar.2019.00182. eCollection 2019.
8
Cancer Biomarkers for Integrative Oncology.癌症综合肿瘤学的生物标志物。
Curr Oncol Rep. 2019 Mar 5;21(4):32. doi: 10.1007/s11912-019-0782-6.
9
Gancao (Glycyrrhizae Radix) provides the main contribution to Shaoyao-Gancao decoction on enhancements of CYP3A4 and MDR1 expression via pregnane X receptor pathway in vitro.甘草（甘草根）通过孕烷 X 受体途径在体外对芍药甘草汤增强 CYP3A4 和 MDR1 表达的主要贡献。
BMC Complement Altern Med. 2018 Dec 29;18(1):345. doi: 10.1186/s12906-018-2402-7.
10
Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective.中草药有助于控制结直肠癌化疗引起的副作用：进展与展望
Front Pharmacol. 2018 Dec 7;9:1442. doi: 10.3389/fphar.2018.01442. eCollection 2018.